CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.
You may also be interested in...
Aceon User Fee Deadline Extended To Allow For Clinical Trial Site Audits
Audits of European clinical trial sites have shown “more audit observations than the FDA was comfortable with,” CV Therapeutics says. The 90-day extension will allow for further audits of the EUROPA trial sites. CVT may add a product for its cardiovascular sales team to promote alongside Aceon and Ranexa.
Aceon User Fee Deadline Extended To Allow For Clinical Trial Site Audits
Audits of European clinical trial sites have shown “more audit observations than the FDA was comfortable with,” CV Therapeutics says. The 90-day extension will allow for further audits of the EUROPA trial sites. CVT may add a product for its cardiovascular sales team to promote alongside Aceon and Ranexa.
Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications
CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.